SEC Form SC 13G/A filed

2/10/21 9:53:41 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALRN alert in real time by email

SC 13G/A 1 ALRN1220.txt 13G AMENDED ANNUAL FILING (ALRN) Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Name of Issuer: Aileron Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 00887A105 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number 00887A105 1. Name of Reporting Person: Jennison Associates LLC S.S. or I.R.S. Identification No. of Above Person: IRS Identification #52-2069785 (formerly 13-2631108) 2. Check the Appropriate Box if a Member of a Group: Not Applicable 3. SEC Use Only 4. Citizenship or Place of Organization: Delaware Number of Shares Beneficially Owned By Each Reporting Person With: 5. Sole Voting Power: 1,542,288** shares 6. Shared Voting Power: 0 shares 7. Sole Dispositive Power: 0 shares 8. Shared Dispositive Power: 1,542,288** shares 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 1,542,288** shares 10. Check Box if the Aggregate Amount in Row 9 Excludes Certain Shares: ( ) 11. Percent of Class Represented by Amount in Row 9: 3.7% 12. Type of Reporting Person*: IA ** Includes 1,542,288 shares of Common Stock which Reporting Person has the right to acquire within 60 days of this filing through the exercise of warrants issued. Item 1(a) Name of Issuer: Aileron Therapeutics, Inc. Item 1(b) Address of Issuer's Principal Executive Offices: (Address of principal executive office) 290 Pleasant Street, Unit 112 Watertown, MA 02472 Item 2(a) Name of Person Filing: Jennison Associates LLC Item 2(b) Address of Principal Business Office or Residence: 466 Lexington Avenue New York, NY 10017 Item 2(c) Citizenship: Delaware Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 00887A105 Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), or (c) check whether the person filing is a: (a) ( ) Broker or Dealer registered under Section 15 of the Act (b) ( ) Bank as defined in Section 3(a) (6) of the Act (c) ( ) Insurance Company as defined in Section 3(a) (19) of the Act (d) ( ) Investment Company registered under Section 8 of the Investment Company Act (e) (X) Investment Adviser in accordance with Section 240.13d-1(b) (1) (ii) (E) (f) ( ) Employee Benefit Plan, Pension Fund which is subject to the provision of the Employee Retirement Income Security Act of 1974 or Endowment Fund in accordance with Section 240.13d-1(b) (ii) (F) (g) ( ) Parent Holding Company or control person, in accordance with Section 240.13(b) (ii) (G) (h) ( ) A savings association as defined by Section 3(b) of the Federal Deposit Insurance Act (i)( ) A church plan that is excluded from the definition of an investment company under Section 3(c) (4) of the Investment Company Act of 1940. (j)( ) Group, in accordance with Section 240.13d-1(b) (1) (ii) (J). If this statement is filed pursuant to Section 240.13d-1(c), check this box. ( ) Item 4 Ownership: Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 1,542,288** (b) Percent of Class: 3.7% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: 1,542,288** (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 1,542,288** ** Includes 1,542,288 shares of Common Stock which Reporting Person has the right to acquire within 60 days of this filing through the exercise of warrants issued. Jennison Associates LLC ("Jennison") furnishes investment advice to several investment companies, insurance separate accounts, and institutional clients ("Managed Portfolios"). As a result of its role as investment adviser of the Managed Portfolios, Jennison may be deemed to be the beneficial owner of the shares of the Issuer's Common Stock held by such Managed Portfolios. Prudential Financial, Inc. ("Prudential") indirectly owns 100% of equity interests of Jennison. As a result, Prudential may be deemed to have the power to exercise or to direct the exercise of such voting and/or dispositive power that Jennison may have with respect to the Issuer's Common Stock held by the Managed Portfolios. Jennison does not file jointly with Prudential, as such, shares of the Issuer's Common Stock reported on Jennison's 13G may be included in the shares reported on the 13G filed by Prudential. These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Jennison is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares. Item 5 Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the securities, check the following (X). Item 6 Ownership of More than Five Percent on Behalf of Another Person: Our clients have the right to receive or the power to direct the receipt of dividends or the profits from the sale of such securities. No one client owns more than 5% of such security class. Item 7 Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company: Not Applicable Item 8 Identification and Classification of Members of the Group: Not Applicable Item 9 Notice of Dissolution of Group: Not Applicable Item 10 Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are in held the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the correct information set forth in this statement is true, complete and correct. February 9, 2021 /s/ Beata Markowicz Beata Markowicz Vice President

Get the next $ALRN alert in real time by email

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for $ALRN

$ALRN Market Insights

Live Market Insights

Aileron Therapeutics Included In The Russell Microcap Index

Aileron Therapeutics Q1 2024 GAAP EPS $(0.86) Misses $(0.14) Estimate

Aileron Therapeutics shares are trading lower after the company announced the pricing of an underwritten registered direct offering of 4,273,505 shares and accompanying warrants at a combined offering price of $4.68.

$ALRN Press Releases

Fastest customizable press release news feed in the world

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

$ALRN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Windsor James Brian bought $758 worth of shares (225 units at $3.37) (SEC Form 4)

Windsor James Brian bought $9,987 worth of shares (5,076 units at $1.97), increasing direct ownership by 11,035% to 5,122 units (SEC Form 4)

$ALRN Financials

Live finance-specific insights

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

$ALRN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Aileron Therapeutics Inc. (Amendment)

SEC Form SC 13G filed by Aileron Therapeutics Inc.

SEC Form SC 13G/A filed by Aileron Therapeutics Inc. (Amendment)

$ALRN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Aivado Manuel

SEC Form 4 filed by Director Von Rickenbach Josef H

SEC Form 4 filed by Director Fairey William

$ALRN Leadership Updates

Live Leadership Updates

Aileron Therapeutics to be Included in the Russell Microcap® Index

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Aileron Therapeutics Announces CEO Transition

$ALRN SEC Filings

SEC Form 8-K filed by Aileron Therapeutics Inc.

SEC Form 10-Q filed by Aileron Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Aileron Therapeutics Inc.

Recent Analyst Ratings for
$ALRN

$ALRN
Market Insights

$ALRN
Press Releases

$ALRN
Insider Purchases

$ALRN
Financials

$ALRN
Large Ownership Changes

$ALRN
Insider Trading

$ALRN
Leadership Updates

$ALRN
SEC Filings